Serafin Morales Murilo

13PUBLICATIONS
102CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Dec 01, 2025
Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial.

Mafalda Oliveira, Eva Ciruelos, Guillermo Villacampa

|Dec 01, 2025
Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer.

Esther Sanfeliu, Anabel Martínez-Romero, Mercedes Marín-Aguilera

|Sep 10, 2025
A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer.

Luis Manso, Rodrigo Sánchez-Bayona, Juan Antonio Guerra

|Jun 04, 2025
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.

María Gion, Isabel Blancas, Patricia Cortez-Castedo

|Apr 01, 2024
First-line therapy with palbociclib in patients with advanced HR+/HER2- breast cancer: The real-life study PALBOSPAIN.

N Martínez-Jañez, M Bellet Ezquerra, L M Manso Sanchez

|Nov 22, 2023
A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer.

David W Cescon, John Hilton, Serafin Morales Murilo

Pageof 3

Frequent Collaborators

5 joint publications

Mafalda Oliveira

4 joint publications

Luis Manso

4 joint publications

Aleix Prat

3 joint publications

Noelia Martínez